墨西哥裔美国老年人认知障碍的人口可归因部分
Mellanie V Springer1, Wen Chang2, Steven G Heeringa2
1Department of Neurology and Stroke Program, University of Michigan, 1500 E. Medical Center drive, Ann Arbor, MI, USA. mvsprin@med.umich.edu.
Journal of racial and ethnic health disparities
|October 14, 2025
概括
低教育和心脏病明显增加了轻度认知障碍 (MCI) 和阿尔茨海默病 (AD/ADRD) 在墨西哥裔美国成年人的病例. 解决这些因素可以预防超过一半的ADRD病例.
科学领域:
- 神经学 神经学
- 公共卫生 公共卫生
- 老年学是指老年学的学科.
背景情况:
- 可修改的风险因素对轻度认知障碍 (MCI) 和阿尔茨海默病及相关痴呆症 (AD/ADRD) 在西班牙裔/拉丁裔 (a,o,x) 成人的影响尚不清楚.
- 了解这些贡献对于有针对性的预防策略至关重要.
研究的目的:
- 为了确定MCI和AD/ADRD的人口归因分数 (PAF).
- 通过解决可修改的风险因素来量化潜在消除病例的比例.
主要方法:
- 在墨西哥裔美国老年人 (2018-2023) 的潜在队列中进行横截面分析.
- 逻辑回归用于根据教育,并发症,吸烟和酒精使用来评估可能的MCI/ADRD的几率.
- 用单个和组合可修改风险因素计算的PAF.
主要成果:
- 在1272名参与者中,MCI的患病率为48%,AD/ADRD的患病率为23%.
- 低教育程度显示,MCI的PAF为17%,AD/ADRD的PAF为52%.
- 心血管因素 (心脏病,糖尿病,中风) 和消除所有因素与MCI和AD/ADRD的显著PAF相关.
结论:
- 低教育程度和心血管相关疾病是墨西哥裔美国成年人中MCI和AD/ADRD的主要原因.
- 针对这些可修改的风险因素的干预措施可以大大降低这一群体认知衰退的负担.
相关概念视频
Cognitive Development During Adulthood
772
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
772
Bias in Epidemiological Studies
1.3K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.3K
Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
Surveys
16.6K
Often, psychologists develop surveys as a means of gathering data. Surveys are lists of questions to be answered by research participants, and can be delivered as paper-and-pencil questionnaires, administered electronically, or conducted verbally. Generally, the survey itself can be completed in a short time, and the ease of administering a survey makes it easy to collect data from a large number of people.
16.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


